Specialty pharmaceutical company, BioSyent Inc., said its subsidiary BioSyent Pharma has launched a sterile topical anesthetic called Cathejell Jelly 2% for the Canadian healthcare market.
Cathejell Jelly 2% combines a sterile gel and lidocaine in a collapsible applicator syringe which provides a safe and effective solution for patients to ease the discomfort of a range of medical procedures, and can also be used for the symptomatic treatment of pain in connection with cystitis and urethritis.
The new sterile anesthetic is indicated for surface anesthesia and lubrication for various procedures, including endoscopies, proctoscopies, and rectoscopies; male and female cystoscopies, catheterizations and other endourethral operations, and tracheal intubations.
Health Canada in July 2011 approved Cathejell Jelly 2%, which was in-licensed by BioSyent Pharma from Pharmazeutische Fabrik MONTAVIT of Absam, Austria (MONTAVIT).
Cathejell Jelly 2%, in addition to Canada, is available in England, Germany, France, Switzerland, Sweden, Italy and Spain.
